Overview

A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma

Status:
Unknown status

Trial end date:
2021-01-01

Target enrollment:

Participant gender:

Summary

A single-arm, open-label clinical trial, focus on the safety and efficacy of TQB2450 injection combined with Anlotinib hydrochloride capsule in patients with advanced biliary adenocarcinoma/hepatocellular carcinoma

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.